Cowen & Co. analyst Oliver Chen maintains Walmart (NYSE:WMT) with a Outperform and lowers the price target from $180 to $150.
Theriva Biologics To Discuss The Trial Design For VIRAGE – A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting
Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength
